These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 18572453)

  • 21. The pharmacogenomics of warfarin (Coumadin) administration.
    Ruano G; Bower B
    Conn Med; 2006 Apr; 70(4):251-2. PubMed ID: 16768072
    [No Abstract]   [Full Text] [Related]  

  • 22. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients.
    Meckley LM; Wittkowsky AK; Rieder MJ; Rettie AE; Veenstra DL
    Thromb Haemost; 2008 Aug; 100(2):229-39. PubMed ID: 18690342
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Fifty years of clinical use of warfarin].
    Quintero-González JA
    Invest Clin; 2010 Jun; 51(2):269-87. PubMed ID: 20928982
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic mechanisms for hypersensitivity and resistance to the anticoagulant Warfarin.
    Linder MW
    Clin Chim Acta; 2001 Jun; 308(1-2):9-15. PubMed ID: 11412812
    [TBL] [Abstract][Full Text] [Related]  

  • 25. VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients.
    Obayashi K; Nakamura K; Kawana J; Ogata H; Hanada K; Kurabayashi M; Hasegawa A; Yamamoto K; Horiuchi R
    Clin Pharmacol Ther; 2006 Aug; 80(2):169-78. PubMed ID: 16890578
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identifying the genotype behind the phenotype: a role model found in VKORC1 and its association with warfarin dosing.
    Crawford DC; Ritchie MD; Rieder MJ
    Pharmacogenomics; 2007 May; 8(5):487-96. PubMed ID: 17465713
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exacerbation of hereditary warfarin resistance by azathioprine.
    Pushpakom SP; Gambhir N; Latif A; Hadfield KD; Campbell S; Newman WG
    Clin Appl Thromb Hemost; 2011 Jun; 17(3):293-6. PubMed ID: 20211925
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Shifting paradigms in the pharmacogenetics of warfarin.
    Gak E; Halkin H
    Pharmacogenomics; 2008 Oct; 9(10):1373-5. PubMed ID: 18855523
    [No Abstract]   [Full Text] [Related]  

  • 29. Multiple genetic alterations in vitamin K epoxide reductase complex subunit 1 gene (VKORC1) can explain the high dose requirement during oral anticoagulation in humans.
    Bodin L; Perdu J; Diry M; Horellou MH; Loriot MA
    J Thromb Haemost; 2008 Aug; 6(8):1436-9. PubMed ID: 18532998
    [No Abstract]   [Full Text] [Related]  

  • 30. Predictors of unstable anticoagulation in African Americans.
    Cavallari LH; Aston JL; Momary KM; Shapiro NL; Patel SR; Nutescu EA
    J Thromb Thrombolysis; 2009 May; 27(4):430-7. PubMed ID: 18563532
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A new VKORC1 mutation leading to an isolated resistance to fluindione.
    Peoc'h K; Pruvot S; Gourmel C; dit Sollier CB; Drouet L
    Br J Haematol; 2009 Jun; 145(6):841-3. PubMed ID: 19344422
    [No Abstract]   [Full Text] [Related]  

  • 32. The challenges of personalized medicine.
    Langman LJ; Snozek CL
    Clin Biochem; 2012 Apr; 45(6):382-3. PubMed ID: 22424083
    [No Abstract]   [Full Text] [Related]  

  • 33. Fluctuations of international normalized ratio in patients treated with oral warfarin therapy in Sneddon's syndrome.
    Lousa M; Gobernado JM; Pardo A
    Eur J Neurol; 1999 Mar; 6(2):255. PubMed ID: 10053242
    [No Abstract]   [Full Text] [Related]  

  • 34. Influence of the VKORC1 3730 G > A polymorphism on warfarin dose.
    Skov J; Bladbjerg EM; Jespersen J
    Eur J Clin Pharmacol; 2013 Apr; 69(4):1043-4. PubMed ID: 23090704
    [No Abstract]   [Full Text] [Related]  

  • 35. The influence of VKORC1 3730 G > A polymorphism on warfarin dose: reply.
    Cini M; Legnani C; Cosmi B; Guazzaloca G; Valdrè L; Frascaro M; Palareti G
    Eur J Clin Pharmacol; 2013 Apr; 69(4):1045. PubMed ID: 23064486
    [No Abstract]   [Full Text] [Related]  

  • 36. Seven cases of interaction between warfarin and cyclooxygenase-2 inhibitors.
    Stading JA; Skrabal MZ; Faulkner MA
    Am J Health Syst Pharm; 2001 Nov; 58(21):2076-80. PubMed ID: 11715832
    [No Abstract]   [Full Text] [Related]  

  • 37. Elevated International Normalized Ratio After Initiation of Niacin and Niacinamide Chemoprophylaxis for Patients on Warfarin.
    Markham DJ; Barbosa NS; Degesys CA
    Dermatol Surg; 2024 Jul; 50(7):690-692. PubMed ID: 38422208
    [No Abstract]   [Full Text] [Related]  

  • 38. Curbside Coumadin Clinics Offer Testing During COVID-19 Crisis.
    Ostroff J; Roggie S; Opitz B
    J Pharm Pract; 2020 Dec; 33(6):734-735. PubMed ID: 32757848
    [No Abstract]   [Full Text] [Related]  

  • 39. Mechanism of bone and cartilage maldevelopment in the warfarin embryopathy.
    Pauli RM
    Pathol Immunopathol Res; 1988; 7(1-2):107-12. PubMed ID: 3222201
    [No Abstract]   [Full Text] [Related]  

  • 40. Commentary on variability in vitamin K antagonist metabolism.
    Smith DA
    Expert Opin Drug Metab Toxicol; 2006 Feb; 2(1):1-2. PubMed ID: 16863463
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.